Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Gains from Investment Securities (2019 - 2024)

Historic Gains from Investment Securities for Fate Therapeutics (FATE) over the last 10 years, with Q3 2024 value amounting to -$942000.0.

  • Fate Therapeutics' Gains from Investment Securities changed N/A to -$942000.0 in Q3 2024 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of -$942000.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2024, Fate Therapeutics' Gains from Investment Securities stood at -$942000.0.
  • Over the past 5 years, Fate Therapeutics' Gains from Investment Securities peaked at $47.8 million during Q1 2020, and registered a low of -$942000.0 during Q3 2024.
  • Its 5-year average for Gains from Investment Securities is $5.7 million, with a median of $291000.0 in 2020.
  • As far as peak fluctuations go, Fate Therapeutics' Gains from Investment Securities soared by 52048.02% in 2020, and later tumbled by 9697.96% in 2021.
  • Quarter analysis of 5 years shows Fate Therapeutics' Gains from Investment Securities stood at $1.2 million in 2020, then soared by 493.77% to $7.1 million in 2021, then plummeted by 97.68% to $164000.0 in 2022, then tumbled by 137.8% to -$62000.0 in 2023, then tumbled by 1419.35% to -$942000.0 in 2024.
  • Its Gains from Investment Securities stands at -$942000.0 for Q3 2024, versus -$62000.0 for Q4 2023 and $164000.0 for Q3 2022.